Cancer drugs show promise against chronic nerve pain in new study

Chronic nerve pain can be difficult to treat. Unlike pain caused by a temporary injury, neuropathic pain can continue for months or even years after the original nerve damage has occurred. For many people, commonly used pain medicines provide limited relief, while some treatments can cause side effects that affect everyday life.

Now, researchers have identified a possible new pathway involved in chronic nerve pain. A study from researchers at The University of Texas MD Anderson Cancer Centre has found that a protein called BRAF, which is already well known for its role in cancer, may also play an important part in increasing pain signals after nerve injury.

The findings are particularly interesting because medicines that block BRAF are already used in cancer treatment. In experiments involving preclinical models, blocking BRAF signalling reduced sensitivity to pain. This raises the possibility that existing cancer drugs could eventually be studied for treating certain forms of chronic nerve pain.

However, experts caution that this is still early research. The findings have not yet established BRAF inhibitors as a treatment for people with chronic pain, and clinical studies in humans will be needed to determine whether the approach is safe and effective.

The findings may be particularly relevant to cancer patients because some cancer treatments can themselves cause nerve damage.

Chemotherapy-induced peripheral neuropathy can lead to symptoms such as burning pain, tingling,



numbness, sensitivity to touch and shooting or electric shock-like sensations. These symptoms can sometimes continue even after cancer treatment has ended.

Researchers at MD Anderson have previously investigated how chemotherapy-induced nerve pain is linked to changes in NMDA receptor activity.

The new findings add BRAF to this picture and suggest that the protein may be part of the pathway through which nerve damage eventually produces stronger and persistent pain signals.

Despite the potential, it is important not to interpret the study as proof that cancer drugs can currently treat chronic nerve pain.

The research was conducted primarily in preclinical models. Results seen in laboratory and animal studies do not always translate into the same benefits in people.

BRAF inhibitors also have their own potential side effects and are prescribed for specific cancer indications. Their safety, dosage and long-term effects would need to be carefully evaluated if they were to be considered for chronic pain.

The next major step will therefore be clinical research involving people with neuropathic pain.

If human studies eventually show that blocking BRAF can safely reduce persistent pain, the discovery could open up an entirely new treatment strategy. Instead of only trying to reduce the sensation of pain, future therapies could potentially target one of the biological pathways responsible for amplifying pain signals in the first place.